ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 17th World Congress on Gastrointestinal Cancer 2015

 

1 - 4 July 2015 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  2-O Socio-economic status influences likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands Maikel Bakens Received Received
  3-PD Incidence and risk factors of deep venous thrombosis detected by routine surveillance ultrasonography before surgery in patients with gastric cancer Yutaka Tanizawa Received Received
  4-P Biomarker-Directed Therapy for Invasive Gastric Cancer: Characterization of a novel regulator of PI3K/AKT/mTOR signaling SHIKHA SATENDRA SINGH Received Received
  5-O FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. Chiara Cremolini Received Received
  7-PD Clinical outcome of Endoscopic Resection of Rectal Neuroendocrine Tumor- NET registry multicenter study Young Kwan Cho Received Received
  7-O Neuropilin 1 (NRP1) may be Prognostic and Identify a Subgroup of Patients with Metastatic Colorectal Cancer (mCRC) who Benefit from Tivozanib mFOLFOX6 compared to Bevacizumab mFOLFOX6. Michael Needle Received Received
  8-PD Safety and efficacy of desensitization protocols for platinum hypersensitivity reactions Katrina Pedersen Received Received
  8-O Phase II Study of Tivantinib (ARQ 197) in Combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC) Lorenza Rimassa Received Received
  9-PD Use of adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer: a nationwide population-based study in the Netherlands Maikel Bakens Received Received
  10-O KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer Howard Hochster Received Received
  11-O Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC) Axel Grothey Received Received
  11-PD Inexpensive biomarkers for determining individuals at increased risk for colorectal cancer and hence have the repeat screening colonoscopy after the first normal earlier than guidelines recommend Garry Mahon Received Received
  11-P ARHI re-expression inhibits subcutaneous xenograft growth and the lung/liver metastases of human gastric cancer cells (BGC823) in nude mice JINGPING QIU Received Received
  13-PD A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors vs bevacizumab in patients with metastatic colorectal cancer Dawn Batty Received Received
  14-P A Tumor-penetrating Recombinant Protein anti-EGFR-iRGD Enchance Efficacy of Paclitaxel in 3D multicellular spheroids and Gastric Cancer in vivo huizi sha Received Received
  14-PD First-line treatment with modified FOLFOX6 (mFOLFOX6) panitumumab or bevacizumab in patients with RAS/BRAF wild-type metastatic colorectal carcinoma Dawn Batty Received Received
  14-O High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. Halfdan Sorbye Received Received
  15-PD A survey on current RAS-mutation testing practices in Europe Emma Earnshaw Received Received
  16-O Exploratory analysis of tumor growth rate in patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib in the GRID phase 3 trial Christian Kappeler Received Received
  17-PD A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE) Tomohiro Nishina Received Received
  18-P Desacetyl isovaltratum, an extract from Valeriana, induces G2/M phase arrest and apoptosis in gastric cancer cell lines Bo Zhang Received Received
  18-PD Modifiable risk factors for colorectal cancer: a multinational case-control study Borys Hrinczenko Received Received
  22-P Expression of Circulating Annexin A2 in Hepatic Diseases and Hepatocellular Carcinoma Ebtesam Elgezawy Received Received
  25-P Long non-coding RNA AOC4P suppressed hepatocellular carcinoma metastasis by inhibiting epithelial-mesenchymal transition Tong-Hong Wang Received Received
  29-P NEUROENDOCRINE TUMORS (NETs). RESPONSE TO CHEMOTHERAPY BY HISTOLOGICAL GRADE. EXPERIENCE CENTER. Cynthia Scarlet Gonzalez Rivas Received Received
  33-P Fruit consumption and ed gastrointestinal cancers morbidity in Poland in the years 1990-2012 Miroslaw Jarosz Received Received
  34-P Red meat consumption and ed gastrointestinal cancers morbidity in Poland in the years 1990-2012 Miroslaw Jarosz Received Received
  35-P P11 is a potential prognostic marker in pancreatic cancer patients and contributes to cancer cell invasion Moamen Bydoun Received Received
  36-P Phase II study of Gemcitabine and Curcumin (Meriva) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data. Caterina Soldà Received Received
  39-P Increased expression of monocarboxylate transporters 1 and 4 and carbonic anhydrase IX in pancreatic ductal adenocarcinomas Ana Marques Received Received
  41-P PATTERNS OF FAILURE IN PANCREATIC CANCER: RESULTS REVIEW M Victoria De Torres Olombrada Received Received
  42-P Institutional experience in induction chemotherapy and neoadjuvant IMRT for borderline resectable and locally advanced pancreatic adenocarcinoma M Victoria De Torres Received Received
  44-P Preoperative chemoradiotherapy in locally advanced esophageal carcinoma: Data from a multidisciplinary oncologic center. Maria Saigi Morgui Received Received
  47-P Perioperative chemotherapy (ECF/FLOT/EOX) for esophagogastric adenocarcinoma: Impact of postoperative chemotherapy on outcome Jens Hoeppner Received Received
  50-P The role of radiotherapy or chemoradiotherapy for oligo-reccurence of esophageal cancer after curative resection or chemoradiotherapy Toshihiko Matsumoto Received Received
  51-P Is Minimally Invasive Esophagectomy Oncologically Safe? Results of a Case-Control Study MARISA ARAL Received Received
  52-P Outcomes of Minimally Invasive Esophagectomy versus Open Esophagectomy for Esophageal Cancer: a Single-Center Case-Control Study MARISA ARAL Received Received
  53-P MET Overexpression and Amplification Define a Distinct Molecular Subgroup for Targeted Therapies in Gastric Cancer Jia Wei Received Received
  54-P Evaluation of driver mutations involving in RAS-RAF/PI3K-mToR pathway in gastric signet ring cell carcinoma Baorui Liu Received Received
  55-P High BIM mRNA levels associated with longer survival in advanced gastric cancer Nandie Wu Received Received
  59-P Can high levels of preoperative carbohydrate antigen 19-9 be a predictor of survival in gastric cancer? Ana Rita Garcia Received Received
  60-P Intestinal versus Diffuse Gastric Cancer Chemoradiation for all or do we need different therapeutic approaches? Ana Rita Garcia Received Received
  70-P Phase I dose-finding study of S-1 in combination with docetaxel and oxaliplatin (DOS) as first-line therapy in patients with advanced gastro-esophageal cancer. Per Pfeiffer Received Received
  77-P TRIGGER FACTOR IN STOMACH MALT-LYMPHOMA Makhsud Mallaev Received Received
  78-P SMALL CELL STOMACH MALT-LYMPHOMA Makhsud Mallaev Received Received
  79-P Impact of disease biology and stage on outcomes for oesophageal and gastric adenocarcinoma (OGA) treated with neoadjuvant chemotherapy. Elisa Fontana Received Received
  80-P STAGING ECHOENDOSCOPY IN ESOPHAGOGASTRIC CANCER PATIENTS ONGOING SURGERY Ana Villaescusa Received Received
  81-P Serum tumor markers as predictors of overall response rate and clinical benefit in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy Silvia Patricia Cortez Castedo Received Received
  83-P Prognostic determinants in gastric cancer survival - the importance of metastatic lymph node ratio Amanda Nogueira Received Received
  84-P GASTRIC CANCER - THE REALITY OF AN INSTITUTION Nadine Saraiva Received Received
  86-P Trastuzumab induced cardiotoxicity in Her2 positive metastatic oeso-gastric cancers Jerome MARTIN-BABAU Received Received
  88-P Evaluation of prognostic and predictive factors in second-line treatment with irinotecan based chemotherapy in gastric cancer. Renata Biernacka Received Received
  89-P TREATMENT OF METASTATIC GASTRIC CANCER WITH DOCETAXEL-IRINOTECAN COMBINATION. VIRGEN DE LAS NIEVES UNIVERSITY HOSPITAL EXPERIENCE. VERONICA CONDE HERRERO Received Received
  93-P HER2 protein over-expression in early stage gastric cancer: correlation with clinicopathological features and survival. Tugba Yavuzsen Received Received
  94-P FDG PET/CT AS A PREOPERATIVE STAGING MODALITY FOR EARLY GASTRIC CANCER. Hyungwoo Oh Received Received
  97-P Double tract reconstruction after laparoscopic proximal gastrectomy; its procedure and short-term results Kazuyuki Kojima Received Received
  98-P LOCAL ADVANCED GASTRIC CANCER: OPTIMIZATION OF MANAGEMENT Oleg Kshivets Received Received
  99-P THE FREQUENCY OF POSITIVE PERITONEAL WASHING IN PATIENTS WITH T4a STAGE GASTRIC CANCER: LONG-TERM RESULTS OF RADICAL SURGERY Ramiz Bayramov Received Received
  102-P Results of surgical therapy for loco-regional recurrence of gastric cancer Anna Chayka Received Received
  107-P Topoisomerase II Alpha (TopoIIa) As A Prognostic Biomarker In Hepatocellular Carcinoma Heba El Zawahry Received Received
  108-P Systematic evaluation of serum inflammatory markers for prognostication of hepatocellular carcinoma (HCC) Lam Chan Received Received
  112-P Local combination therapy with chemoembolization and microwave ablation in patients with Hepatocellular Carcinoma a single center experience. Hermina Fernandes Received Received
  114-P A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma Ahmed Kaseb Received Received
  115-P Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. Valentina Angela Marsico Received Received
  116-P Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver Eric Wachter Received Received
  117-P Sarcopenia at First Diagnosis Predicts a Reduced Survival in Patients Affected by Hepatocarcinoma Paola Begini Received Received
  122-P Concurrent Chemotherapy and Volumetric Modulated Arc Therapy (VMAT ) in carcinoma of the anal canal- Reduction of acute gastrointestinal and genitourinary toxicity kaloyan yordanov Received Received
  123-P Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery Astrid Slagter Received Received
  127-P Efficacy of Y-Shaped Bilateral Self-Expandable Metallic Stent Placement in Patients with Unresectable Hilar Cholangiocarcinoma Jong Jin Hyun Received Received
  128-P Efficacy of Various Endoscopic Transpapillary Sampling Methods for Malignant Biliary Lesions Jong Jin Hyun Received Received
  129-P Cisplatin plus Gemcitabine in Elderly patients with advanced biliary tract carcinoma: Torrecardenas Hospital Experience. CASTELLÓN RUBIO VICTORIA EUGENIA Received Received
  130-P Predictors of malignancy in biliary mucin-producing cystic neoplasms Sung Yong Han Received Received
  141-P Combined versus sequential adjuvant therapy of biliary tract cancer: what is the best option? Alessandra Cassano Received Received
  143-P Weight Loss during chemotherapy in patients with advanced Oesophagogastric (OG) and Hepatobiliary-Pancreatic (HPB) cancers is not a surrogate for disease progression. GEORGIOS OIKONOMOPOULOS Received Received
  145-P Prospective Phase II Trial of Combination Treatment of Whole Hepatic Irradiation and Hyperthermia in Chemorefractory Numerous Hepatic Metastases of Gastrointestinal Malignancy Jeong Il Yu Received Received
  146-P STENTING METASTATIC BILE DUCT OBSTRUCTION (BDO): THE IMPORTANCE OF LIVER FUNCTION PARAMETERS Milana Bergamino Sirvén Received Received
  153-P Impact of comorbidity on the survival of patients with cholangiocarcinoma Elizabeth Inga Received Received
  156-P Biliary drainage in patients with extrahepatic bile ducts cancer and obstructive jaundice Vladislav Stoyanov Received Received
  157-P Mitomycin C, 5-Fluorouracyl and Doxorubicin combination as a second-line chemotherapy in unresectable and metastatic biliary tract carcinoma: results of the first stage Agata Kuchar Received Received
  159-P Gastric myoelectric activity disturbances in patients with gastric and colorectal cancer. Preliminary study. Zygulska Aneta Received Received
  160-P Estimation of autonomic nervous system activity by heart rate and blood pressure variability in patients with gastric and colorectal cancer. Preliminary study. Aneta Zygulska Received Received
  161-P A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment. Emmanuelle SAMALIN Received Received
  162-P Interim Results of IMMU-132 (Sacituzumab Govitecan), an Anti-Trop-2 Antibody-Drug Conjugate (ADC), in Patients (pts) with Metastatic Gastrointestinal (GI) Cancers. Arlene Powell Received Received
  163-P Is KRAS status prognostic or predictive for anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer? Hironaga Satake Received Received
  164-P GEMCITABINE VERSUS FOLFIRINOX IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA HENT1 POSITIVE: BACK TO THE FUTURE. Maria Alessandra Calegari Received Received
  166-P Decrement of Serum CA 19-9 Concentration after Initial Chemotherapy Predicts Favorable Outcome in Patients with Advanced Pancreatic Cancer JIKON RYU Received Received
  167-P Risk factors for febrile neutropenia in patients with unresectable pancreatic cancer receiving FOLFIRINOX as the first-line treatment. Mitsuhito Sasaki Received Received
  168-P Definitive 3D concurrent chemoradiotherapy in locally advanced pancreatic cancer Abdelgawad Marwa Received Received
  172-P Efficacy and safety of S-1 and gemcitabine in an uned Western cohort of patients with unresectable pancreatic cancer. Per Pfeiffer Received Received
  174-P The role of gastroenterologists in providing initial information on treatment options for patients with pancreatic cancer (PC) in the United States and Europe: a global quantitative survey Andrew Rhim Received Received
  177-P Phase II trial of capecitabine nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma Werner Scheithauer Received Received
  178-P First-line chemotherapy with gemcitabine in advanced pancreatic cancer: a retrospective single-center analysis Helena Magalhaes Received Received
  179-P Gemcitabine plus nab-Paclitaxel in metastatic or locally inoperable pancreatic cancer a single center experience Ursula Vogl Received Received
  183-P NEOADJUVANT TREATMENT IN BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: A SINGLE CENTER SERIES Helena Verdaguer Mata Received Received
  184-P nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study Hanno Riess Received Received
  185-P Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT Margaret Tempero Received Received
  186-P International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT Philip Philip Received Received
  190-P Feasibility of using MicroRNAs in early detection of recurrence in colon cancer patients Jesper Olsen Received Received
  193-P Downregulation of CDX2 is associated with MMR-deficiency but not recurrence in colon cancer Jesper Olsen Received Received
  195-P SPRY2 AND RESPONSE TO FOLFOX/CAPOX IN METASTATIC KRAS MUTATED COLORECTAL CANCER Robert Montal Received Received
  197-P Number of CD68() macrophages and FasL expression in colon mucosa of patients with inflammatory bowel disease as prognostic factors of colon carcinogenesis Andrei Santimov Received Received
  198-P Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. Marta Schirripa Received Received
  206-P Efficacy and tolerance of a simplified combination of Streptozotocine and epi-adriamycine in metastatic foregut neuroendocrine tumor (NET). Laure Hirsch Received Received
  212-P The cost of survival gain in metastatic colorectal cancer (mCRC) in France Whalen John Received Received
  213-P The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain John Whalen Received Received
  214-P Pattern of Dipkoff-2 gene expression in tumoral tissues of colorectal cancer and two tumor tissues of colorectal cancer and three cell lines (HUVEC, SW480 and HCT116) Farnaz Khodarahmi Received Received
  216-P Effect on colorectal cancer patients anxiety levels of planned following at home Ilknur Aydin Avci Received Received
  222-P Detection of colorectal dysplasia using fluorescently-labeled lectins Joe C Kuo Received Received
  223-P The first experience in Intraoperative Radiation Therapy for locally advanced or recurrent rectal cancer Sergey Potemin Received Received
  229-P BODY FAT MASS AND THE RISK OF COLORECTAL POLYPS IN MEN AND WOMEN Miroslaw Jarosz Received Received
  230-P Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in France Karin Sennfalt Received Received
  233-P Economic impact of biomarker-based anti EGFR therapies in metastatic colorectal cancer in Austria Dora Nieders-Beke Received Received
  234-P The Intestinal Stem Cell Marker SOX9 Predicts Relapse of Stage II Colon Cancer Patients Maiken Lise Marcker Espersen Received Received
  235-P Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC) Vincenzo Ricci Received Received
  236-P Other RAS mutations incidence in CRCm in routine clinical practice: a center experience. Beatriz González Received Received
  237-P K-RAS exon 2 mutations in advanced colorectal cancer: are they really so bad prognostic indicators? A mono-insititutional retrospective study Vincenzo Dadduzio Received Received
  238-P Circulating epidermal growth factor-like domain 7 of prognostic importance in patients with metastatic colorectal cancer Torben Hansen Received Received
  240-P Did the mRNA cutoff copy numbers in peripheral blood influence their relationship with prognosis in stage I-III colorectal cancer patients Yong Liu Received Received
  241-P FEASIBILITY AND RESULTS OF EXPANDED RAS GENOTIPYNG IN AN ARGENTINEAN PUBLIC HOSPITAL Silvina Otero Received Received
  244-P Prospective study of S-1Irinotecan plus bevacizumab as second-line therapy in Japanese patients with metastatic colorectal cancer (KSCC1102) Hironaga Satake Received Received
  245-P Cetuximab with infusional or oral fluorouracil in 1st line treatment for metastatic colorectal cancer: a comparison study Hironaga Satake Received Received
  246-P Feasibility study of sequential adjuvant chemotheraphy with three months oxaliplatin-based regimen followed by three months capecitabine in patients with stage III and high risk stage II colorectal cancer: (JSWOG C2) Hiroaki Tanioka Received Received
  250-P Clinical Impact and Cost Implication of Routine MMR Protein Immunohistochemistry in High Risk Dukes B Colon Cancer Kevin Chiu Received Received
  254-P A multicentre, non-interventional, post-authorization study to observe in daily clinical practice the treatment duration of patients treated with bevacizumab in 1st line mCRC in Belgium. Dieter Frijns Received Received
  255-P A randomized, placebo-controlled, double-blind phase II trial of peri-operative cimetidine in early colorectal cancer Michael Jameson Received Received
  256-P An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD) faysal dane Received Received
  257-P Intensity of adjuvant chemotherapy regimens among elderly stage III colon cancer patients Felice van Erning Received Received
  258-P Grade III-IV toxicities among elderly stage III colon cancer patients receiving CAPOX or capecitabine Felice van Erning Received Received
  259-P Recurrence-free survival according to treatment modality among elderly stage III colon cancer patients Felice van Erning Received Received
  261-P Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC) Isrid Sturm Received Received
  266-P Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience. Beatriz González Received Received
  267-P Systemic therapy and surgery improve overall survival compared with surgery alone after curative liver resection of colorectal metastases: a single-center study from Costa Rica Allan Ramos-Esquivel Received Received
  270-P Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong Ka-On LAM Received Received
  271-P Retrospective Cohort Study on the Safety and Efficacy of Regorafenib for Metastatic Colorectal Cancer Patients : The HGCSG1401 Study -First Report- SATOSHI YUKI Received Received
  272-P Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab Susana Rodríguez Received Received
  273-P Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing Rodney Scott Received Received
  274-P Nodal status predict pathologic complete response following preoperative chemotherapy for colorectal liver metastases LOURDES CALERA Received Received
  275-P Phase II study of oral tegafur/uracil and leucovorin plus bevacizumab as a first line therapy for elderly patients with advanced or metastatic colorectal cancer Hiroshi Tamagawa Received Received
  276-P S-1 and oxaliplatin (SOx) in older Western patients with metastatic colorectal cancer (mCRC) Per Pfeiffer Received Received
  277-P Increased Carcinoembryonic antigen (CEA) predicts poor prognosis in patients after neoadjuvant chemotherapy that undergo hepatectomy for liver-only colorectal metastases and especially in those who dont receive post-hepatectomy adjuvant chemotherapy Mafalda Costa Neves Received Received
  279-P CETUXIMAB AS THIRD LINE TREATMENT OF METASTATIC COLORECTAL CARCINOMA (mCRC) 5-YEAR EXPERIENCE FROM THE INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA Jelena Spasic Received Received
  281-P The GERCOR and Khne prognostic models in metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based first-line therapy: comparison and validation of both models in a real-life setting Gema Bruixola Received Received
  282-P Palliative chemotherapy for patients 70 and above with metastatic colorectal cancer: How Much Chemotherapy is Enough? Dominick Bossé Received Received
  283-P Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial. alessandro passardi Received Received
  284-P Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup Alfredo Falcone Received Received
  285-P Treatment of metastatic colorectal cancer. Experience of Centro Javeriano de Oncología - Hospital Universitario San Ignacio, Bogotá, Colombia Annie Katherine Natera Melo Received Received
  292-P The Polyp Manager: a new tool to report polyps during colonoscopy in a complete and time efficient way. A pilot study. Maartje van de Meeberg Received Received
  295-P CA 11-19: A Tumor Marker to Detect Colorectal Cancer lisa jensen-long Received Received
  296-P Preventive intraperitoneal chemotherapy in colon cancers with high risk of recurrence: outcome at 5 years from a prospective study Anissa Ourabah Received Received
  297-P Anastomotic leakage in patients operated for colorectal cancer in a high volume UK centre within an enhanced recovery programme setting Jimmy Ng Received Received
  298-P Perioperative Oral Nutritional Support in Colorectal Cancer Patients May Improve Clinical and Health Economics Outcomes Viktor Manasek Received Received
  299-P Contrast medium marking for gastrointestinal stenting Jun Ninomiya Received Received
  304-P RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy. Phillip Strauss Received Received
  305-P A phase II biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer Anna Schab Received Received
  306-P A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer Eduardo Vilar Received Received
  311-P A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE) Michel Ducreux Received Received
  313-P K-ras mutation as prognostic factor in our patients with rectal cancer Danijela Scepanovic Received Received
  317-P Outcome of elderly patients with non-metastatic rectal cancer: a retrospective study Marc-André Bureau Received Received
  319-P Angiogenesis evaluation in locally advanced colo-rectal and gastric cancers by probe-based Confocal Laser Endomicroscopy (pCLE) Renato Cannizzaro Received Received
  322-P CONCOMITENT RADIOCHEMOTHERAPY IN ELDERLY PATIENTS WITH LOCALLY-ADVANCED RECTAL CANCER Rodica Anghel Received Received
  323-P CISPLATIN PLUS CAPECITABINE (CisCape) AND RADIOTHERAPY (RT) FOR THE NEOADJUVANT TREATMENT OF RECTAL CANCER: FINAL UPDATE OF PREVIOUSLY REPORTED DATA Laura Martano Received Received
  325-P A Phase II trial using a combination of Oxaliplatin, Capecitabine, and Celecoxib with concurrent radiation for newly diagnosed resectable rectal cancer: COX2 expression in relationship to outcomes Emilio Araujo-Mino Received Received
  327-P BIOLOGIC THERAPY IN THE MANAGEMENT OF LOCALLY ADVANCED RECTAL CANCER, EXPERIENCE OF 20 DE NOVIEMBRE ISSSTE MEDICAL CENTER, MEXICO CITY Josue Mora Perez Received Received
  328-P Which is the best first approach for liver-only synchronic metastasis rectal cancer? Ismael Ghanem Received Received
  329-P Reintroduction of oxaliplatin for patients with metastatic colorectal cancer Marija Ristic Received Received
  331-P Organ sparing radiotherapy in rectal cancer: definitive chemoradiation is a safe and valid option. Rachel Brooker Received Received
  334-P RADIOLOGICAL ASSESSMENTS FOR SELECT PATIENTS IN NEOADJUVANT SETTING IN RECTAL CANCER: MONOISTITUTIONAL EXPERIENCE roberto murialdo Received Received
  338-P Non-Operative Treatment after Neo-Adjuvant Short Course Radiotherapy (The Tlalpan Regime) in a combined modality for Locally Advanced Rectal Cancer with risk factors at the Instituto Nacional de Cancerología (México) Jesus Zamora-Moreno Received Received
  340-P Value of Pelvic Index for prediction of anastomotic leakage after laparoscopic low anterior resection in male rectal cancer ATSUSHI TSURUTA Received Received
  342-P Standardized Technique of Laparoscopic Extralevator Abdominoperineal Excision (LAP-ELAPE) Madoka Hamada Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
02:36
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 17th World Congress on Gastrointestinal Cancer 2015

 

1 - 4 July 2015 Barcelona
HELP LINE
Manage Orders
FAQs

THE SUBMISSION DEADLINE HAS BEEN EXTENDED UNTIL MONDAY 6TH JULY AT 23:00 GMT+1.

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 01/07/2015 TO 01/07/2016
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.17wcgc.2015 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 06/07/2015
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster






PosterSessionOnline
Logo Draft
 
Logo Cert